Company Profile
InSilico Medicine Cayman TopCo applyies artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. The company offers Pharma.AI, an AI-powered drug discovery and development platform offering new target identification, small molecule generation, and clinical outcome prediction services. Its pipeline covers solutions for fibrosis, oncology, immunology, metabolic, anti-pain, and therapeutic areas.
The company is also involved in R&D collaboration, software solutions, business development, new drug discovery, and holding company businesses. The company has a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. for the development of oligonucleotide therapeutics
Strategic collaboration with Human Life Foundation Models, Inc. for the development of foundation models for human longevity science. It operates in Hong Kong, the United States, the United Kingdom, Kingdom of Saudi Arabia, Japan, Denmark, the United Arab Emirates, Korea, Mainland China, Germany, Switzerland, Taiwan, and globally. Founded in 2014, the company is based in New Territories, Hong Kong.